Proactiveinvestors Australia Merck & Co., Inc. https://www.proactiveinvestors.com.au Proactiveinvestors Australia Merck & Co., Inc. RSS feed en Thu, 04 Jun 2020 05:53:57 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Merck Head of Pacific BD&L sees a 'coming of age' in how the immune system plays role in neuroscience https://www.proactiveinvestors.com.au/companies/news/905465/merck-head-of-pacific-bdl-sees-a--coming-of-age--in-how-the-immune-system-plays-role-in-neuroscience-905465.html Wed, 23 Oct 2019 14:50:00 +1100 https://www.proactiveinvestors.com.au/companies/news/905465/merck-head-of-pacific-bdl-sees-a--coming-of-age--in-how-the-immune-system-plays-role-in-neuroscience-905465.html The Edge CEO: Why Merck & Co should spin off its animal health division https://www.proactiveinvestors.com.au/companies/news/312022/the-edge-ceo-why-merck--co-should-spin-off-its-animal-health-division-12022.html Thu, 07 Feb 2019 17:16:00 +1100 https://www.proactiveinvestors.com.au/companies/news/312022/the-edge-ceo-why-merck--co-should-spin-off-its-animal-health-division-12022.html Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda https://www.proactiveinvestors.com.au/companies/news/201752/merck-s-2q-earnings-beat-street-with-sales-turbocharged-by-cancer-drug-keytruda-201752.html Fri, 27 Jul 2018 13:04:00 +1000 https://www.proactiveinvestors.com.au/companies/news/201752/merck-s-2q-earnings-beat-street-with-sales-turbocharged-by-cancer-drug-keytruda-201752.html Merck posts better-than-expected 1Q profits due to sales of its drug Keytruda https://www.proactiveinvestors.com.au/companies/news/196161/merck-posts-better-than-expected-1q-profits-due-to-sales-of-its-drug-keytruda-196161.html Tue, 01 May 2018 13:59:00 +1000 https://www.proactiveinvestors.com.au/companies/news/196161/merck-posts-better-than-expected-1q-profits-due-to-sales-of-its-drug-keytruda-196161.html Merck shares pop as its Keytruda drug results power ahead of Bristol-Myers, Roche https://www.proactiveinvestors.com.au/companies/news/195075/merck-shares-pop-as-its-keytruda-drug-results-power-ahead-of-bristol-myers-roche-195075.html Mon, 16 Apr 2018 16:10:00 +1000 https://www.proactiveinvestors.com.au/companies/news/195075/merck-shares-pop-as-its-keytruda-drug-results-power-ahead-of-bristol-myers-roche-195075.html Merck & Co shares rise thanks to success of Phase 3 lung cancer trial https://www.proactiveinvestors.com.au/companies/news/194523/merck-co-shares-rise-thanks-to-success-of-phase-3-lung-cancer-trial-194523.html Mon, 09 Apr 2018 12:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/194523/merck-co-shares-rise-thanks-to-success-of-phase-3-lung-cancer-trial-194523.html Leucadia National, Merck & Co, Franklin Resources, Menlo Therapeutics - PRE-MARKET https://www.proactiveinvestors.com.au/companies/news/194521/leucadia-national-merck-co-franklin-resources-menlo-therapeutics-pre-market-194521.html Mon, 09 Apr 2018 11:59:00 +1000 https://www.proactiveinvestors.com.au/companies/news/194521/leucadia-national-merck-co-franklin-resources-menlo-therapeutics-pre-market-194521.html Merck & Co's quarterly loss widens as it takes US$2.6bn hit due to US tax changes https://www.proactiveinvestors.com.au/companies/news/191077/merck-co-s-quarterly-loss-widens-as-it-takes-us26bn-hit-due-to-us-tax-changes-191077.html Fri, 02 Feb 2018 13:24:00 +1100 https://www.proactiveinvestors.com.au/companies/news/191077/merck-co-s-quarterly-loss-widens-as-it-takes-us26bn-hit-due-to-us-tax-changes-191077.html Merck shares continue to rise after successful lung cancer trial https://www.proactiveinvestors.com.au/companies/news/190178/merck-shares-continue-to-rise-after-successful-lung-cancer-trial-190178.html Wed, 17 Jan 2018 14:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/190178/merck-shares-continue-to-rise-after-successful-lung-cancer-trial-190178.html Merck shares slip premarket after hiking outlook following mixed bag of third quarter results https://www.proactiveinvestors.com.au/companies/news/186352/merck-shares-slip-premarket-after-hiking-outlook-following-mixed-bag-of-third-quarter-results-186352.html Fri, 27 Oct 2017 12:22:00 +1100 https://www.proactiveinvestors.com.au/companies/news/186352/merck-shares-slip-premarket-after-hiking-outlook-following-mixed-bag-of-third-quarter-results-186352.html KalVista Pharmaceuticals boosted by Merck tie-up https://www.proactiveinvestors.com.au/companies/news/185347/kalvista-pharmaceuticals-boosted-by-merck-tie-up-185347.html Tue, 10 Oct 2017 12:13:00 +1100 https://www.proactiveinvestors.com.au/companies/news/185347/kalvista-pharmaceuticals-boosted-by-merck-tie-up-185347.html Merck discontinues one of its hepatitis C virus drug development programs https://www.proactiveinvestors.com.au/companies/news/184864/merck-discontinues-one-of-its-hepatitis-c-virus-drug-development-programs-184864.html Fri, 29 Sep 2017 18:43:00 +1000 https://www.proactiveinvestors.com.au/companies/news/184864/merck-discontinues-one-of-its-hepatitis-c-virus-drug-development-programs-184864.html Merck & Co cuts full year profit guidance; agrees drug collaboration with AstraZeneca https://www.proactiveinvestors.com.au/companies/news/181649/merck-co-cuts-full-year-profit-guidance-agrees-drug-collaboration-with-astrazeneca-181649.html Fri, 28 Jul 2017 13:51:00 +1000 https://www.proactiveinvestors.com.au/companies/news/181649/merck-co-cuts-full-year-profit-guidance-agrees-drug-collaboration-with-astrazeneca-181649.html Merck shares slide as drugs giant forced to halt enrolment of two late-stage cancer studies https://www.proactiveinvestors.com.au/companies/news/179158/merck-shares-slide-as-drugs-giant-forced-to-halt-enrolment-of-two-late-stage-cancer-studies-179158.html Tue, 13 Jun 2017 13:25:00 +1000 https://www.proactiveinvestors.com.au/companies/news/179158/merck-shares-slide-as-drugs-giant-forced-to-halt-enrolment-of-two-late-stage-cancer-studies-179158.html Merck gets Keytruda go-ahead as a first line lung cancer treatment https://www.proactiveinvestors.com.au/companies/news/177659/merck-gets-keytruda-go-ahead-as-a-first-line-lung-cancer-treatment-177659.html Thu, 11 May 2017 12:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/177659/merck-gets-keytruda-go-ahead-as-a-first-line-lung-cancer-treatment-177659.html Merck & Co raises forecasts again as new drugs prove worth https://www.proactiveinvestors.com.au/companies/news/177167/merck-co-raises-forecasts-again-as-new-drugs-prove-worth-177167.html Tue, 02 May 2017 13:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/177167/merck-co-raises-forecasts-again-as-new-drugs-prove-worth-177167.html Merck receives diabetes drug labelling setback https://www.proactiveinvestors.com.au/companies/news/176169/merck-receives-diabetes-drug-labelling-setback-176169.html Fri, 07 Apr 2017 15:13:00 +1000 https://www.proactiveinvestors.com.au/companies/news/176169/merck-receives-diabetes-drug-labelling-setback-176169.html Cancer drug Keytruda lifts Merck https://www.proactiveinvestors.com.au/companies/news/172578/cancer-drug-keytruda-lifts-merck-172578.html Thu, 02 Feb 2017 15:16:00 +1100 https://www.proactiveinvestors.com.au/companies/news/172578/cancer-drug-keytruda-lifts-merck-172578.html US FDA agrees to accelerated review of Merck immunotherapy drug combination treatment for lung cancer https://www.proactiveinvestors.com.au/companies/news/171479/us-fda-agrees-to-accelerated-review-of-merck-immunotherapy-drug-combination-treatment-for-lung-cancer-171479.html Wed, 11 Jan 2017 13:41:00 +1100 https://www.proactiveinvestors.com.au/companies/news/171479/us-fda-agrees-to-accelerated-review-of-merck-immunotherapy-drug-combination-treatment-for-lung-cancer-171479.html Merck's Keytruda close to Europe approval as chemotherapy alternative https://www.proactiveinvestors.com.au/companies/news/170613/merck-s-keytruda-close-to-europe-approval-as-chemotherapy-alternative-170613.html Fri, 16 Dec 2016 14:43:00 +1100 https://www.proactiveinvestors.com.au/companies/news/170613/merck-s-keytruda-close-to-europe-approval-as-chemotherapy-alternative-170613.html Gilead order to pay US$2.54bn in royalties after losing patent battle https://www.proactiveinvestors.com.au/companies/news/170608/gilead-order-to-pay-us254bn-in-royalties-after-losing-patent-battle-170608.html Fri, 16 Dec 2016 13:49:00 +1100 https://www.proactiveinvestors.com.au/companies/news/170608/gilead-order-to-pay-us254bn-in-royalties-after-losing-patent-battle-170608.html Bristol Myers suffers again after more Keytruda success https://www.proactiveinvestors.com.au/companies/news/167163/bristol-myers-suffers-again-after-more-keytruda-success-167163.html Mon, 10 Oct 2016 14:22:00 +1100 https://www.proactiveinvestors.com.au/companies/news/167163/bristol-myers-suffers-again-after-more-keytruda-success-167163.html Merck/Pfizer ready new diabetes drug after trial success https://www.proactiveinvestors.com.au/companies/news/165958/merckpfizer-ready-new-diabetes-drug-after-trial-success-165958.html Thu, 15 Sep 2016 13:58:00 +1000 https://www.proactiveinvestors.com.au/companies/news/165958/merckpfizer-ready-new-diabetes-drug-after-trial-success-165958.html Merck axes osteoporosis treatment odanacatib https://www.proactiveinvestors.com.au/companies/news/147662/merck-axes-osteoporosis-treatment-odanacatib-147662.html Fri, 02 Sep 2016 13:04:00 +1000 https://www.proactiveinvestors.com.au/companies/news/147662/merck-axes-osteoporosis-treatment-odanacatib-147662.html Jefferies keeps Merck medicine on the shelf https://www.proactiveinvestors.com.au/companies/news/122138/jefferies-keeps-merck-medicine-on-the-shelf-122138.html Wed, 03 Feb 2016 18:46:00 +1100 https://www.proactiveinvestors.com.au/companies/news/122138/jefferies-keeps-merck-medicine-on-the-shelf-122138.html NewLink Genetics and Merck vaccine shown to be 100% effective against Ebola https://www.proactiveinvestors.com.au/companies/news/115138/newlink-genetics-and-merck-vaccine-shown-to-be-100-effective-against-ebola-115138.html Fri, 31 Jul 2015 16:45:00 +1000 https://www.proactiveinvestors.com.au/companies/news/115138/newlink-genetics-and-merck-vaccine-shown-to-be-100-effective-against-ebola-115138.html Merck posts Q2 profit beat, sales miss; full-year EPS forecast boosted https://www.proactiveinvestors.com.au/companies/news/115137/merck-posts-q2-profit-beat-sales-miss-full-year-eps-forecast-boosted-115137.html Tue, 28 Jul 2015 16:34:00 +1000 https://www.proactiveinvestors.com.au/companies/news/115137/merck-posts-q2-profit-beat-sales-miss-full-year-eps-forecast-boosted-115137.html Merck boosts annual profit forecast, reports Q1 profit and sales beat https://www.proactiveinvestors.com.au/companies/news/106443/merck-boosts-annual-profit-forecast-reports-q1-profit-and-sales-beat-61194.html Tue, 28 Apr 2015 14:44:00 +1000 https://www.proactiveinvestors.com.au/companies/news/106443/merck-boosts-annual-profit-forecast-reports-q1-profit-and-sales-beat-61194.html Merck acquires OncoEthix for up to $375 mln to boost cancer drug pipeline https://www.proactiveinvestors.com.au/companies/news/104769/merck-acquires-oncoethix-for-up-to-375-mln-to-boost-cancer-drug-pipeline-58905.html Thu, 18 Dec 2014 18:47:00 +1100 https://www.proactiveinvestors.com.au/companies/news/104769/merck-acquires-oncoethix-for-up-to-375-mln-to-boost-cancer-drug-pipeline-58905.html Merck to acquire Cubist for $8.4 bln to push deeper into antibiotics https://www.proactiveinvestors.com.au/companies/news/104554/merck-to-acquire-cubist-for-84-bln-to-push-deeper-into-antibiotics-58622.html Mon, 08 Dec 2014 13:40:00 +1100 https://www.proactiveinvestors.com.au/companies/news/104554/merck-to-acquire-cubist-for-84-bln-to-push-deeper-into-antibiotics-58622.html Merck slides as Q3 net drops, sales miss estimates; full-year guidance narrowed https://www.proactiveinvestors.com.au/companies/news/103849/merck-slides-as-q3-net-drops-sales-miss-estimates-full-year-guidance-narrowed-57682.html Mon, 27 Oct 2014 18:50:00 +1100 https://www.proactiveinvestors.com.au/companies/news/103849/merck-slides-as-q3-net-drops-sales-miss-estimates-full-year-guidance-narrowed-57682.html Merck edges higher as Q2 results beat, 2014 guidance lifted https://www.proactiveinvestors.com.au/companies/news/102533/merck-edges-higher-as-q2-results-beat-2014-guidance-lifted-55764.html Tue, 29 Jul 2014 14:22:00 +1000 https://www.proactiveinvestors.com.au/companies/news/102533/merck-edges-higher-as-q2-results-beat-2014-guidance-lifted-55764.html Merck to buy Idenix for $3.85 bln https://www.proactiveinvestors.com.au/companies/news/101706/merck-to-buy-idenix-for-385-bln-54621.html Mon, 09 Jun 2014 13:54:00 +1000 https://www.proactiveinvestors.com.au/companies/news/101706/merck-to-buy-idenix-for-385-bln-54621.html Merck drops after selling consumer care unit to Bayer for $14.2 bln https://www.proactiveinvestors.com.au/companies/news/101174/merck-drops-after-selling-consumer-care-unit-to-bayer-for-142-bln-53909.html Tue, 06 May 2014 14:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/101174/merck-drops-after-selling-consumer-care-unit-to-bayer-for-142-bln-53909.html Merck hits new 52-week high after Q1 earnings top estimates https://www.proactiveinvestors.com.au/companies/news/101071/merck-hits-new-52-week-high-after-q1-earnings-top-estimates-53749.html Tue, 29 Apr 2014 19:57:00 +1000 https://www.proactiveinvestors.com.au/companies/news/101071/merck-hits-new-52-week-high-after-q1-earnings-top-estimates-53749.html Wall Street shares up with Fed meeting and Twitter in focus https://www.proactiveinvestors.com.au/companies/news/101057/wall-street-shares-up-with-fed-meeting-and-twitter-in-focus-53735.html Tue, 29 Apr 2014 14:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/101057/wall-street-shares-up-with-fed-meeting-and-twitter-in-focus-53735.html Merck drops F'13 forecast, beats profit estimate in Q3 https://www.proactiveinvestors.com.au/companies/news/98135/merck-drops-f13-forecast-beats-profit-estimate-in-q3-49302.html Mon, 28 Oct 2013 14:26:00 +1100 https://www.proactiveinvestors.com.au/companies/news/98135/merck-drops-f13-forecast-beats-profit-estimate-in-q3-49302.html Merck shares slide on outlook, delay for osteoporosis treatment approval  https://www.proactiveinvestors.com.au/companies/news/92800/merck-shares-slide-on-outlook-delay-for-osteoporosis-treatment-approval-40146.html Fri, 01 Feb 2013 14:34:00 +1100 https://www.proactiveinvestors.com.au/companies/news/92800/merck-shares-slide-on-outlook-delay-for-osteoporosis-treatment-approval-40146.html Merck Q3 earnings edge up despite decline in sales https://www.proactiveinvestors.com.au/companies/news/90743/merck-q3-earnings-edge-up-despite-decline-in-sales-36544.html Fri, 26 Oct 2012 13:10:00 +1100 https://www.proactiveinvestors.com.au/companies/news/90743/merck-q3-earnings-edge-up-despite-decline-in-sales-36544.html Merck to relocate headquarters to save money, reduce “real estate footprint” https://www.proactiveinvestors.com.au/companies/news/90221/merck-to-relocate-headquarters-to-save-money-reduce-real-estate-footprint-35714.html Tue, 09 Oct 2012 17:43:00 +1100 https://www.proactiveinvestors.com.au/companies/news/90221/merck-to-relocate-headquarters-to-save-money-reduce-real-estate-footprint-35714.html Merck Q2 profit off on restructuring charge, but core earnings beat on higher revenue https://www.proactiveinvestors.com.au/companies/news/88268/merck-q2-profit-off-on-restructuring-charge-but-core-earnings-beat-on-higher-revenue-32563.html Fri, 27 Jul 2012 13:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/88268/merck-q2-profit-off-on-restructuring-charge-but-core-earnings-beat-on-higher-revenue-32563.html Merck rallies after phase III trial for osteoporosis drug closing early on "robust" results https://www.proactiveinvestors.com.au/companies/news/87853/merck-rallies-after-phase-iii-trial-for-osteoporosis-drug-closing-early-on-robust-results-31893.html Thu, 12 Jul 2012 17:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/87853/merck-rallies-after-phase-iii-trial-for-osteoporosis-drug-closing-early-on-robust-results-31893.html Merck Q1 profit jumps 67% https://www.proactiveinvestors.com.au/companies/news/85720/merck-q1-profit-jumps-67-28328.html Fri, 27 Apr 2012 14:11:00 +1000 https://www.proactiveinvestors.com.au/companies/news/85720/merck-q1-profit-jumps-67-28328.html Endocyte shares surge on partnership with Merck for cancer drug https://www.proactiveinvestors.com.au/companies/news/85362/endocyte-shares-surge-on-partnership-with-merck-for-cancer-drug-27757.html Mon, 16 Apr 2012 14:11:00 +1000 https://www.proactiveinvestors.com.au/companies/news/85362/endocyte-shares-surge-on-partnership-with-merck-for-cancer-drug-27757.html Merck expects flat sales for 2012, Q4 profits top Street https://www.proactiveinvestors.com.au/companies/news/83360/merck-expects-flat-sales-for-2012-q4-profits-top-street-24379.html Thu, 02 Feb 2012 13:09:00 +1100 https://www.proactiveinvestors.com.au/companies/news/83360/merck-expects-flat-sales-for-2012-q4-profits-top-street-24379.html Merck boosts full year view, Q3 results top forecasts https://www.proactiveinvestors.com.au/companies/news/80960/merck-boosts-full-year-view-q3-results-top-forecasts-20291.html Fri, 28 Oct 2011 13:23:00 +1100 https://www.proactiveinvestors.com.au/companies/news/80960/merck-boosts-full-year-view-q3-results-top-forecasts-20291.html Merck announces positive interim results of ISENTRESS drug in phase 3 HIV trial https://www.proactiveinvestors.com.au/companies/news/80552/merck-announces-positive-interim-results-of-isentress-drug-in-phase-3-hiv-trial-19635.html Thu, 13 Oct 2011 19:27:00 +1100 https://www.proactiveinvestors.com.au/companies/news/80552/merck-announces-positive-interim-results-of-isentress-drug-in-phase-3-hiv-trial-19635.html Merck, Ariad announce FDA accepts NDA filing, review for cancer drug https://www.proactiveinvestors.com.au/companies/news/80349/merck-ariad-announce-fda-accepts-nda-filing-review-for-cancer-drug-19303.html Wed, 05 Oct 2011 17:12:00 +1100 https://www.proactiveinvestors.com.au/companies/news/80349/merck-ariad-announce-fda-accepts-nda-filing-review-for-cancer-drug-19303.html Merck and BGI to collaborate on biomarker and genomic technologies research https://www.proactiveinvestors.com.au/companies/news/79784/merck-and-bgi-to-collaborate-on-biomarker-and-genomic-technologies-research-18302.html Tue, 13 Sep 2011 15:43:00 +1000 https://www.proactiveinvestors.com.au/companies/news/79784/merck-and-bgi-to-collaborate-on-biomarker-and-genomic-technologies-research-18302.html Merck, Roche expand deal to promote Victrelis hep C drug globally https://www.proactiveinvestors.com.au/companies/news/78737/merck-roche-expand-deal-to-promote-victrelis-hep-c-drug-globally-16493.html Wed, 20 Jul 2011 16:23:00 +1000 https://www.proactiveinvestors.com.au/companies/news/78737/merck-roche-expand-deal-to-promote-victrelis-hep-c-drug-globally-16493.html Merck reports positive phase 2 results for HIV drug, shows additional insights https://www.proactiveinvestors.com.au/companies/news/78680/merck-reports-positive-phase-2-results-for-hiv-drug-shows-additional-insights--16397.html Mon, 18 Jul 2011 15:59:00 +1000 https://www.proactiveinvestors.com.au/companies/news/78680/merck-reports-positive-phase-2-results-for-hiv-drug-shows-additional-insights--16397.html Merck and Hanwha ink deal to develop biosimilar Enbrel https://www.proactiveinvestors.com.au/companies/news/78049/merck-and-hanwha-ink-deal-to-develop-biosimilar-enbrel-15382.html Mon, 13 Jun 2011 15:32:00 +1000 https://www.proactiveinvestors.com.au/companies/news/78049/merck-and-hanwha-ink-deal-to-develop-biosimilar-enbrel-15382.html Merck and Intercell terminate trials for Staph vaccine following independent review https://www.proactiveinvestors.com.au/companies/news/77972/merck-and-intercell-terminate-trials-for-staph-vaccine-following-independent-review-15251.html Wed, 08 Jun 2011 12:37:00 +1000 https://www.proactiveinvestors.com.au/companies/news/77972/merck-and-intercell-terminate-trials-for-staph-vaccine-following-independent-review-15251.html Merck's hepatitis C drug receives positive recommendation from EMA https://www.proactiveinvestors.com.au/companies/news/77690/mercks-hepatitis-c-drug-receives-positive-recommendation-from-ema-14788.html Fri, 20 May 2011 14:46:00 +1000 https://www.proactiveinvestors.com.au/companies/news/77690/mercks-hepatitis-c-drug-receives-positive-recommendation-from-ema-14788.html Merck to buy eye drug maker Inspire Pharmaceuticals for $430m https://www.proactiveinvestors.com.au/companies/news/77011/merck-to-buy-eye-drug-maker-inspire-pharmaceuticals-for-430m-13606.html Tue, 05 Apr 2011 15:01:00 +1000 https://www.proactiveinvestors.com.au/companies/news/77011/merck-to-buy-eye-drug-maker-inspire-pharmaceuticals-for-430m-13606.html Merck To Buy Insulin Developer SmartCells For As Much As $500 Million https://www.proactiveinvestors.com.au/companies/news/75185/merck-to-buy-insulin-developer-smartcells-for-as-much-as-500-million--10549.html Thu, 02 Dec 2010 21:32:00 +1100 https://www.proactiveinvestors.com.au/companies/news/75185/merck-to-buy-insulin-developer-smartcells-for-as-much-as-500-million--10549.html Lundbeck signs commercialization agreement for Merck's bipolar drug https://www.proactiveinvestors.com.au/companies/news/74248/-lundbeck-signs-commercialization-agreement-for-mercks-bipolar-drug-9114.html Tue, 12 Oct 2010 19:08:00 +1100 https://www.proactiveinvestors.com.au/companies/news/74248/-lundbeck-signs-commercialization-agreement-for-mercks-bipolar-drug-9114.html Merck and Sanofi-Aventis to set up JV to boost share in US$19bn animal health market https://www.proactiveinvestors.com.au/companies/news/72362/merck-and-sanofi-aventis-to-set-up-jv-to-boost-share-in-us19bn-animal-health-market-4682.html Tue, 09 Mar 2010 16:33:00 +1100 https://www.proactiveinvestors.com.au/companies/news/72362/merck-and-sanofi-aventis-to-set-up-jv-to-boost-share-in-us19bn-animal-health-market-4682.html Merck to take over Schering-Plough in US$41 billion cash and share deal https://www.proactiveinvestors.com.au/companies/news/69993/merck-to-take-over-schering-plough-in-us41-billion-cash-and-share-deal-1058.html Mon, 09 Mar 2009 16:56:00 +1100 https://www.proactiveinvestors.com.au/companies/news/69993/merck-to-take-over-schering-plough-in-us41-billion-cash-and-share-deal-1058.html